RCUS · NYSE
Arcus Biosciences, Inc.
$18.20 +0.53 (+3.00%)
Company overview
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes cancer therapies in the United States. Its pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 clinical trials, and Zimberelimab, an anti-PD-1 antibody in Phase 1b clinical trials for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor in Phase 1/1b studies for first-line metastatic pancreatic cancer; and AB521, an oral small-molecule HIF-2α inhibitor in Phase 1 studies for von Hippel-Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca and BVF Partners L.P.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NYSE
- Market cap
- $2.3B
- Employees
- 627
- Headquarters
- Hayward, CA
- Website
- arcusbio.com
- CEO
- Terry J. Rosen
- Listed
- March 15, 2018
- P/E
- -5.75
- Dividend yield
- 0.00%
Company financials
- Revenue
- $236M
- Gross profit
- $229M
- Operating income
- -$398M
- EBITDA
- -$339M
- Net income
- -$369M
- EPS
- -$3.17
- Total assets
- $997M
- Total debt
- $100M
- Gross margin
- 97.03%
- Net margin
- -156.36%
- Earnings yield
- -17.40%
No geographic segmentation.
Showing FY 2025
RCUS
1D
NYSE
O18.32H18.62L17.63C17.67-0.87 (-4.69%)Vol789.70K